Switch to:
Also traded in: Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.07
FMS's Cash to Debt is ranked lower than
77% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 0.31 vs. FMS: 0.07 )
Ranked among companies with meaningful Cash to Debt only.
FMS' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.06 Max: N/A
Current: 0.07
Equity to Asset 0.38
FMS's Equity to Asset is ranked lower than
60% of the 219 Companies
in the Global Medical Care industry.

( Industry Median: 0.45 vs. FMS: 0.38 )
Ranked among companies with meaningful Equity to Asset only.
FMS' s Equity to Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.40 Max: 0.5
Current: 0.38
0.34
0.5
Interest Coverage 4.27
FMS's Interest Coverage is ranked lower than
69% of the 157 Companies
in the Global Medical Care industry.

( Industry Median: 9.36 vs. FMS: 4.27 )
Ranked among companies with meaningful Interest Coverage only.
FMS' s Interest Coverage Range Over the Past 10 Years
Min: 3.55  Med: 4.82 Max: 6.3
Current: 4.27
3.55
6.3
F-Score: 6
Z-Score: 2.57
M-Score: -2.46
WACC vs ROIC
4.13%
9.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 13.89
FMS's Operating margin (%) is ranked higher than
74% of the 219 Companies
in the Global Medical Care industry.

( Industry Median: 7.46 vs. FMS: 13.89 )
Ranked among companies with meaningful Operating margin (%) only.
FMS' s Operating margin (%) Range Over the Past 10 Years
Min: 13.87  Med: 15.69 Max: 16.51
Current: 13.89
13.87
16.51
Net-margin (%) 6.23
FMS's Net-margin (%) is ranked higher than
62% of the 220 Companies
in the Global Medical Care industry.

( Industry Median: 4.28 vs. FMS: 6.23 )
Ranked among companies with meaningful Net-margin (%) only.
FMS' s Net-margin (%) Range Over the Past 10 Years
Min: 6.32  Med: 7.65 Max: 8.6
Current: 6.23
6.32
8.6
ROE (%) 11.16
FMS's ROE (%) is ranked higher than
58% of the 202 Companies
in the Global Medical Care industry.

( Industry Median: 9.24 vs. FMS: 11.16 )
Ranked among companies with meaningful ROE (%) only.
FMS' s ROE (%) Range Over the Past 10 Years
Min: 11.55  Med: 13.36 Max: 14.68
Current: 11.16
11.55
14.68
ROA (%) 4.23
FMS's ROA (%) is ranked higher than
52% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 3.51 vs. FMS: 4.23 )
Ranked among companies with meaningful ROA (%) only.
FMS' s ROA (%) Range Over the Past 10 Years
Min: 4.52  Med: 5.63 Max: 6.22
Current: 4.23
4.52
6.22
ROC (Joel Greenblatt) (%) 40.06
FMS's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 20.18 vs. FMS: 40.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
FMS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 38.32  Med: 44.37 Max: 50.61
Current: 40.06
38.32
50.61
Revenue Growth (3Y)(%) 10.60
FMS's Revenue Growth (3Y)(%) is ranked higher than
66% of the 160 Companies
in the Global Medical Care industry.

( Industry Median: 8.20 vs. FMS: 10.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
FMS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -4.6  Med: 6.20 Max: 17.2
Current: 10.6
-4.6
17.2
EBITDA Growth (3Y)(%) 6.70
FMS's EBITDA Growth (3Y)(%) is ranked lower than
55% of the 128 Companies
in the Global Medical Care industry.

( Industry Median: 7.90 vs. FMS: 6.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
FMS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 7.90 Max: 43.1
Current: 6.7
0
43.1
EPS Growth (3Y)(%) 1.60
FMS's EPS Growth (3Y)(%) is ranked lower than
67% of the 118 Companies
in the Global Medical Care industry.

( Industry Median: 9.00 vs. FMS: 1.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
FMS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -17.6  Med: 13.35 Max: 62.7
Current: 1.6
-17.6
62.7
» FMS's 10-Y Financials

Financials (Next Earnings Date: 2016-02-24)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

FMS Guru Trades in Q4 2014

Manning & Napier Advisors, Inc 279,080 sh (unchged)
John Keeley 40,000 sh (unchged)
Jim Simons 21,900 sh (-73.84%)
» More
Q1 2015

FMS Guru Trades in Q1 2015

Jim Simons 61,300 sh (+179.91%)
Manning & Napier Advisors, Inc 312,560 sh (+12.00%)
John Keeley 40,000 sh (unchged)
» More
Q2 2015

FMS Guru Trades in Q2 2015

John Keeley 40,000 sh (unchged)
Manning & Napier Advisors, Inc 312,560 sh (unchged)
Jim Simons 40,558 sh (-33.84%)
» More
Q3 2015

FMS Guru Trades in Q3 2015

John Keeley 40,000 sh (unchged)
Manning & Napier Advisors, Inc 312,560 sh (unchged)
Manning & Napier Advisors, Inc 312,560 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with FMS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Fresenius Medical Care AG & Co. KGaA

SymbolPriceYieldDescription
FMCMF67.800.00
FME3.Germany54.200.96
FMSPR0.001.06ADR

Top Ranked Articles about Fresenius Medical Care AG & Co. KGaA

Weekly 52-Week Highs Highlight: FMS, MTB, LO, LEN
According to GuruFocus list of 52-week highs, Fresenius Medical Care AG & Co, M&T Bank Corp, Lorillard Inc, and Lennar Corp have all reached their 52-week highs. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 25.36
FMS's P/E(ttm) is ranked higher than
53% of the 265 Companies
in the Global Medical Care industry.

( Industry Median: 27.90 vs. FMS: 25.36 )
Ranked among companies with meaningful P/E(ttm) only.
FMS' s P/E(ttm) Range Over the Past 10 Years
Min: 13.32  Med: 20.03 Max: 29.39
Current: 25.36
13.32
29.39
Forward P/E 18.08
FMS's Forward P/E is ranked lower than
57% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 16.75 vs. FMS: 18.08 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 25.36
FMS's PE(NRI) is ranked lower than
51% of the 202 Companies
in the Global Medical Care industry.

( Industry Median: 24.85 vs. FMS: 25.36 )
Ranked among companies with meaningful PE(NRI) only.
FMS' s PE(NRI) Range Over the Past 10 Years
Min: 13.2  Med: 20.02 Max: 29.4
Current: 25.36
13.2
29.4
P/B 2.69
FMS's P/B is ranked lower than
53% of the 303 Companies
in the Global Medical Care industry.

( Industry Median: 2.53 vs. FMS: 2.69 )
Ranked among companies with meaningful P/B only.
FMS' s P/B Range Over the Past 10 Years
Min: 1.69  Med: 2.47 Max: 3.01
Current: 2.69
1.69
3.01
P/S 1.51
FMS's P/S is ranked lower than
57% of the 301 Companies
in the Global Medical Care industry.

( Industry Median: 1.26 vs. FMS: 1.51 )
Ranked among companies with meaningful P/S only.
FMS' s P/S Range Over the Past 10 Years
Min: 1.03  Med: 1.51 Max: 1.89
Current: 1.51
1.03
1.89
PFCF 24.80
FMS's PFCF is ranked lower than
61% of the 202 Companies
in the Global Medical Care industry.

( Industry Median: 20.37 vs. FMS: 24.80 )
Ranked among companies with meaningful PFCF only.
FMS' s PFCF Range Over the Past 10 Years
Min: 14.18  Med: 23.75 Max: 54
Current: 24.8
14.18
54
POCF 13.24
FMS's POCF is ranked higher than
60% of the 275 Companies
in the Global Medical Care industry.

( Industry Median: 14.09 vs. FMS: 13.24 )
Ranked among companies with meaningful POCF only.
FMS' s POCF Range Over the Past 10 Years
Min: 9.49  Med: 12.66 Max: 19.48
Current: 13.24
9.49
19.48
EV-to-EBIT 14.30
FMS's EV-to-EBIT is ranked higher than
64% of the 290 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. FMS: 14.30 )
Ranked among companies with meaningful EV-to-EBIT only.
FMS' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.3  Med: 12.20 Max: 16.7
Current: 14.3
7.3
16.7
EV-to-EBITDA 11.08
FMS's EV-to-EBITDA is ranked higher than
60% of the 303 Companies
in the Global Medical Care industry.

( Industry Median: 12.05 vs. FMS: 11.08 )
Ranked among companies with meaningful EV-to-EBITDA only.
FMS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.8  Med: 9.70 Max: 12.9
Current: 11.08
5.8
12.9
PEG 3.24
FMS's PEG is ranked lower than
58% of the 76 Companies
in the Global Medical Care industry.

( Industry Median: 2.75 vs. FMS: 3.24 )
Ranked among companies with meaningful PEG only.
FMS' s PEG Range Over the Past 10 Years
Min: 0.8  Med: 2.00 Max: 23.04
Current: 3.24
0.8
23.04
Shiller P/E 31.28
FMS's Shiller P/E is ranked lower than
55% of the 69 Companies
in the Global Medical Care industry.

( Industry Median: 27.95 vs. FMS: 31.28 )
Ranked among companies with meaningful Shiller P/E only.
FMS' s Shiller P/E Range Over the Past 10 Years
Min: 20.76  Med: 28.42 Max: 42.51
Current: 31.28
20.76
42.51
Current Ratio 1.72
FMS's Current Ratio is ranked higher than
68% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 1.33 vs. FMS: 1.72 )
Ranked among companies with meaningful Current Ratio only.
FMS' s Current Ratio Range Over the Past 10 Years
Min: 0.8  Med: 1.41 Max: 1.93
Current: 1.72
0.8
1.93
Quick Ratio 1.38
FMS's Quick Ratio is ranked higher than
60% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 1.22 vs. FMS: 1.38 )
Ranked among companies with meaningful Quick Ratio only.
FMS' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.15 Max: 1.61
Current: 1.38
0.7
1.61
Days Inventory 37.41
FMS's Days Inventory is ranked lower than
69% of the 157 Companies
in the Global Medical Care industry.

( Industry Median: 16.67 vs. FMS: 37.41 )
Ranked among companies with meaningful Days Inventory only.
FMS' s Days Inventory Range Over the Past 10 Years
Min: 32.59  Med: 35.64 Max: 40.32
Current: 37.41
32.59
40.32
Days Sales Outstanding 72.92
FMS's Days Sales Outstanding is ranked lower than
79% of the 187 Companies
in the Global Medical Care industry.

( Industry Median: 45.70 vs. FMS: 72.92 )
Ranked among companies with meaningful Days Sales Outstanding only.
FMS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 73.86  Med: 80.38 Max: 85.55
Current: 72.92
73.86
85.55
Days Payable 18.86
FMS's Days Payable is ranked lower than
76% of the 144 Companies
in the Global Medical Care industry.

( Industry Median: 42.47 vs. FMS: 18.86 )
Ranked among companies with meaningful Days Payable only.
FMS' s Days Payable Range Over the Past 10 Years
Min: 17.84  Med: 22.38 Max: 35.89
Current: 18.86
17.84
35.89

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.04
FMS's Dividend Yield is ranked lower than
77% of the 249 Companies
in the Global Medical Care industry.

( Industry Median: 2.08 vs. FMS: 1.04 )
Ranked among companies with meaningful Dividend Yield only.
FMS' s Dividend Yield Range Over the Past 10 Years
Min: 0.93  Med: 1.38 Max: 2.07
Current: 1.04
0.93
2.07
Dividend Payout 0.25
FMS's Dividend Payout is ranked higher than
75% of the 146 Companies
in the Global Medical Care industry.

( Industry Median: 0.71 vs. FMS: 0.25 )
Ranked among companies with meaningful Dividend Payout only.
FMS' s Dividend Payout Range Over the Past 10 Years
Min: 0.91  Med: 1.10 Max: 1.36
Current: 0.25
0.91
1.36
Dividend Growth (3y) 6.30
FMS's Dividend Growth (3y) is ranked lower than
64% of the 64 Companies
in the Global Medical Care industry.

( Industry Median: 11.00 vs. FMS: 6.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
FMS' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 8
Current: 6.3
0
8
Forward Dividend Yield 1.04
FMS's Forward Dividend Yield is ranked lower than
74% of the 211 Companies
in the Global Medical Care industry.

( Industry Median: 2.09 vs. FMS: 1.04 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.54
FMS's Yield on cost (5-Year) is ranked lower than
68% of the 257 Companies
in the Global Medical Care industry.

( Industry Median: 2.53 vs. FMS: 1.54 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
FMS' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.36  Med: 2.02 Max: 3.03
Current: 1.54
1.36
3.03
3-Year Average Share Buyback Ratio 0.20
FMS's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 120 Companies
in the Global Medical Care industry.

( Industry Median: -2.20 vs. FMS: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
FMS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -8.7  Med: -0.60 Max: 0.6
Current: 0.2
-8.7
0.6

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.30
FMS's Price/Projected FCF is ranked higher than
60% of the 171 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. FMS: 1.30 )
Ranked among companies with meaningful Price/Projected FCF only.
FMS' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.97  Med: 1.47 Max: 3.18
Current: 1.3
0.97
3.18
Price/DCF (Earnings Based) 1.62
FMS's Price/DCF (Earnings Based) is ranked higher than
53% of the 47 Companies
in the Global Medical Care industry.

( Industry Median: 1.54 vs. FMS: 1.62 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.05
FMS's Price/Median PS Value is ranked higher than
57% of the 300 Companies
in the Global Medical Care industry.

( Industry Median: 1.05 vs. FMS: 1.05 )
Ranked among companies with meaningful Price/Median PS Value only.
FMS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.22  Med: 0.97 Max: 1.76
Current: 1.05
0.22
1.76
Price/Peter Lynch Fair Value 4.13
FMS's Price/Peter Lynch Fair Value is ranked lower than
78% of the 85 Companies
in the Global Medical Care industry.

( Industry Median: 2.47 vs. FMS: 4.13 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
FMS' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.9  Med: 2.01 Max: 4.74
Current: 4.13
0.9
4.74
Earnings Yield (Greenblatt) (%) 6.98
FMS's Earnings Yield (Greenblatt) (%) is ranked higher than
66% of the 211 Companies
in the Global Medical Care industry.

( Industry Median: 4.40 vs. FMS: 6.98 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
FMS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 6  Med: 8.20 Max: 13.7
Current: 6.98
6
13.7
Forward Rate of Return (Yacktman) (%) 9.98
FMS's Forward Rate of Return (Yacktman) (%) is ranked lower than
51% of the 98 Companies
in the Global Medical Care industry.

( Industry Median: 10.04 vs. FMS: 9.98 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
FMS' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -8.2  Med: 11.60 Max: 19.8
Current: 9.98
-8.2
19.8

More Statistics

Revenue(Mil) $16503
EPS $ 1.72
Beta0.36
Short Percentage of Float0.20%
52-Week Range $36.13 - 45.85
Shares Outstanding(Mil)609.66

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 16,859 18,265 19,424
EPS($) 2.20 2.64 2.30
EPS without NRI($) 2.20 2.64 2.30

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, DVA, FSNUY, BDUUF, SKHCY » details
Traded in other countries:FMEN.Germany, FME N.Mexico, FME.Switzerland, 0H9X.UK, FMCMF.USA,
Fresenius Medical Care AG & Co. KGaA was incorporated on August 5, 1996. It is a kidney dialysis company, operating in both the field of dialysis products and the field of dialysis services. The Company's dialysis business is vertically integrated, providing dialysis treatment at its own dialysis clinics and supplying these clinics with different products. In addition, to providing dialysis treatments, includes pharmacy services and vascular access surgery services. It sells dialysis products to other dialysis service providers. It also develops and manufactures equipment, systems and disposable products, which it sells to customers in over 120 countries. It offers life-maintaining and life-saving dialysis services and products in a market which is characterized by a favorable demographic development. It provides expanded and enhanced patient services, including renal pharmaceutical products and laboratory services, to both its own clinics and those of third parties. The Company's clinics also provide services for home dialysis patients, the majority of whom receive peritoneal dialysis treatment. It also provides dialysis services under contract to hospitals in the U.S. on an 'as needed' basis for hospitalized ESRD patients and for patients suffering from acute kidney failure. The Company provides laboratory testing and marketing services in the U.S. through Spectra Laboratories (Spectra). Spectra provides blood, urine and other bodily fluid testing services to determine the appropriate individual dialysis therapy for a patient and to assist physicians in determining whether a dialysis patient's therapy regimen, diet and medicines remain optimal. The Company's main trademarks are the name 'Fresenius' and the 'F' logo'. The Company's competitors in the sale of hemodialysis and peritoneal dialysis products include, Baxter International Inc., Asahi Kasei Kuraray Medical Co. Ltd., Bellco S.r.l., B. Braun Melsungen AG, Nipro Corporation Ltd., Nikkiso Co., Ltd., Terumo Corporation, Kawasumi Laboratories Inc., Fuso Pharmaceuticals Industries Ltd., and Toray Industries, Inc. The Company's operations are subject to extensive governmental regulation by virtually every country in which it operates, including the U.S., at the federal, state and local levels.
» More Articles for FMS

Headlines

Articles On GuruFocus.com
Weekly 52-Week Highs Highlight: FMS, MTB, LO, LEN Apr 05 2015 
Weekly 3-Year Low Highlights: FMS, SNOW, KMDA, LAYN Jun 16 2014 
Weekly 52-Week Highs Highlight: MMP, AZO, BEAM, FMS Jan 26 2014 
Better Know a Company: Fresenius Medical Care (FMS) Apr 23 2013 
Warren Buffett Becomes Largest Owner of DaVita Mar 04 2013 
Warren Buffett’s Holding of DaVita Grows as Company Expands Jan 17 2013 
Buffett’s Berkshire Hathaway Buys Even More DaVita Shares Nov 29 2012 
Edward Owens Buys Walgreen Co., UCBH Holdings Inc., OSI Pharmaceuticals Inc., Sells Ventana Medical Aug 02 2007 
Kenneth Fisher: Surviving Rate Rises Jun 04 2006 

More From Other Websites
Amgen Tops on Q4 Earnings & Revenues, Ups 2016 Outlook Jan 29 2016
Fresenius Medical Care announces change in Management Board Jan 28 2016
Fresenius Medical upgraded by JP Morgan Jan 04 2016
Amgen’s Nephrology Drugs Expect Falling Revenue in 4Q15 Dec 29 2015
FRESENIUS MEDICAL CARE AG & CO. KGAA Financials Dec 08 2015
Amgen’s Bone and Nephrology Drugs Register Solid Growth in 3Q15 Nov 16 2015
Fresenius Finance B.V. -- Moody's upgrades Fresenius SE to Baa3; stable outlook Nov 16 2015
Fresenius Medical Care North America 2015 Health Indicator Survey Finds Americans and Physicians Are... Nov 04 2015
Debiotech and Fresenius Medical Care Announce Exclusive Partnership for New Home Dialysis Product... Nov 03 2015
Fresenius (FMS) Q3 Earnings, Revenues Miss; Outlook Intact Oct 30 2015
Amgen Ups 2015 Outlook with Q3 Earnings & Revenue Beat Oct 29 2015
Fresenius Medical Care reports third quarter 2015 results and confirms guidance for full year 2015 Oct 29 2015
How Does Cantel Medical Compare to Its Peers? Oct 02 2015
Cantel Medical’s Revenue and Income Rose in 4Q15 Oct 01 2015
Fresenius Medical Care provides historical segment data Sep 21 2015
Fresenius Medical Care North America's Nephrology Nurses Recognized for Sacrifice and Dedication to... Sep 17 2015
The Zacks Analyst Blog Highlights: Volkswagen AG, Aixtron SE, SAP SE, Affimed N.V. and Fresenius... Sep 10 2015
Fresenius Medical Care AG & Co. KGaA Earnings Q2, 2015 Sep 01 2015
Ten Years after Hurricane Katrina, Fresenius Medical Care Remembers Heroic Stories, Shares Lessons... Aug 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK